Obsidian Therapeutics, Inc. (OBX)
Obsidian Therapeutics, Inc. (OBX) from its SEC filings: 2025 revenue $0, free cash flow -$90.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $0 |
| Net income | -$100.6 million |
| Free cash flow | -$90.5 million |
| Diluted EPS | $-7.22 |
| Cash | $18.0 million |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.